Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Using data on snus use in Sweden to compare different modelling approaches to estimate the population health impact of introducing a smoke-free tobacco product.

Djurdjevic S, Pecze L, Weitkunat R, Luedicke F, Fry J, Lee P.

BMC Public Health. 2019 Oct 29;19(1):1411. doi: 10.1186/s12889-019-7714-0.

2.

Potential predictors of adoption of the Tobacco Heating System by U.S. adult smokers: An actual use study.

Roulet S, Chrea C, Kanitscheider C, Kallischnigg G, Magnani P, Weitkunat R.

F1000Res. 2019 Feb 24;8:214. doi: 10.12688/f1000research.17606.1. eCollection 2019.

3.

Effects of Switching to a Heat-Not-Burn Tobacco Product on Biologically Relevant Biomarkers to Assess a Candidate Modified Risk Tobacco Product: A Randomized Trial.

Lüdicke F, Ansari SM, Lama N, Blanc N, Bosilkovska M, Donelli A, Picavet P, Baker G, Haziza C, Peitsch M, Weitkunat R.

Cancer Epidemiol Biomarkers Prev. 2019 Nov;28(11):1934-1943. doi: 10.1158/1055-9965.EPI-18-0915. Epub 2019 Jul 3.

PMID:
31270101
4.

Favorable Changes in Biomarkers of Potential Harm to Reduce the Adverse Health Effects of Smoking in Smokers Switching to the Menthol Tobacco Heating System 2.2 for Three Months (Part 2).

Haziza C, de La Bourdonnaye G, Donelli A, Skiada D, Poux V, Weitkunat R, Baker G, Picavet P, Lüdicke F.

Nicotine Tob Res. 2019 May 24. pii: ntz084. doi: 10.1093/ntr/ntz084. [Epub ahead of print]

PMID:
31125079
6.

Developing fit-for-purpose self-report instruments for assessing consumer responses to tobacco and nicotine products: the ABOUT™ Toolbox initiative.

Chrea C, Acquadro C, Afolalu EF, Spies E, Salzberger T, Abetz-Webb L, Cano S, Arnould B, Mainy N, Rose J, Weitkunat R.

F1000Res. 2018 Dec 2;7:1878. doi: 10.12688/f1000research.16810.1. eCollection 2018.

7.

Reduction In Exposure To Selected Harmful And Potentially Harmful Constituents Approaching Those Observed Upon Smoking Abstinence In Smokers Switching To The Menthol Tobacco Heating System 2.2 For Three Months (Part 1).

Haziza C, de La Bourdonnaye G, Donelli A, Poux V, Skiada D, Weitkunat R, Baker G, Picavet P, Lüdicke F.

Nicotine Tob Res. 2019 Feb 5. doi: 10.1093/ntr/ntz013. [Epub ahead of print]

PMID:
30722062
8.

Estimating the population health impact of introducing a reduced-risk tobacco product into Japan. The effect of differing assumptions, and some comparisons with the U.S.

Lee PN, Djurdjevic S, Weitkunat R, Baker G.

Regul Toxicol Pharmacol. 2018 Dec;100:92-104. doi: 10.1016/j.yrtph.2018.10.010. Epub 2018 Oct 24.

9.

Development and validation of a new instrument to measure perceived risks associated with the use of tobacco and nicotine-containing products.

Cano S, Chrea C, Salzberger T, Alfieri T, Emilien G, Mainy N, Ramazzotti A, Lüdicke F, Weitkunat R.

Health Qual Life Outcomes. 2018 Sep 21;16(1):192. doi: 10.1186/s12955-018-0997-5.

10.

Modeling the impact of changes in tobacco use on individual disease risks.

Djurdjevic S, Sponsiello-Wang Z, Lee PN, Fry JS, Weitkunat R, Lüdicke F, Baker G.

Regul Toxicol Pharmacol. 2018 Aug;97:88-97. doi: 10.1016/j.yrtph.2018.06.001. Epub 2018 Jun 9.

PMID:
29894733
11.

Modeling the Population Health Impact of Introducing a Modified Risk Tobacco Product into the U.S. Market.

Djurdjevic S, Lee PN, Weitkunat R, Sponsiello-Wang Z, Lüdicke F, Baker G.

Healthcare (Basel). 2018 May 16;6(2). pii: E47. doi: 10.3390/healthcare6020047.

12.

Review of biomarkers to assess the effects of switching from cigarettes to modified risk tobacco products.

Peck MJ, Sanders EB, Scherer G, Lüdicke F, Weitkunat R.

Biomarkers. 2018 Jan 9:1-32. doi: 10.1080/1354750X.2017.1419284. [Epub ahead of print]

PMID:
29297706
13.

Quantifying the risk-reduction potential of new Modified Risk Tobacco Products.

Martin F, Vuillaume G, Baker G, Sponsiello-Wang Z, Ricci PF, Lüdicke F, Weitkunat R.

Regul Toxicol Pharmacol. 2018 Feb;92:358-369. doi: 10.1016/j.yrtph.2017.12.011. Epub 2017 Dec 16.

14.

Nicotine pharmacokinetic profiles of the Tobacco Heating System 2.2, cigarettes and nicotine gum in Japanese smokers.

Brossard P, Weitkunat R, Poux V, Lama N, Haziza C, Picavet P, Baker G, Lüdicke F.

Regul Toxicol Pharmacol. 2017 Oct;89:193-199. doi: 10.1016/j.yrtph.2017.07.032. Epub 2017 Jul 29.

15.

Estimating the effect of differing assumptions on the population health impact of introducing a Reduced Risk Tobacco Product in the USA.

Lee PN, Fry JS, Hamling JF, Sponsiello-Wang Z, Baker G, Weitkunat R.

Regul Toxicol Pharmacol. 2017 Aug;88:192-213. doi: 10.1016/j.yrtph.2017.06.009. Epub 2017 Jun 24.

16.

Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis.

Marchand M, Brossard P, Merdjan H, Lama N, Weitkunat R, Lüdicke F.

Eur J Drug Metab Pharmacokinet. 2017 Dec;42(6):943-954. doi: 10.1007/s13318-017-0405-2.

19.

Reduced Exposure to Harmful and Potentially Harmful Smoke Constituents With the Tobacco Heating System 2.1.

Lüdicke F, Baker G, Magnette J, Picavet P, Weitkunat R.

Nicotine Tob Res. 2017 Feb;19(2):168-175. doi: 10.1093/ntr/ntw164. Epub 2016 Jul 1.

20.

Evaluation of Biomarkers of Exposure in Smokers Switching to a Carbon-Heated Tobacco Product: A Controlled, Randomized, Open-Label 5-Day Exposure Study.

Lüdicke F, Haziza C, Weitkunat R, Magnette J.

Nicotine Tob Res. 2016 Jul;18(7):1606-13. doi: 10.1093/ntr/ntw022. Epub 2016 Jan 27.

21.

A Japanese cross-sectional multicentre study of biomarkers associated with cardiovascular disease in smokers and non-smokers.

Lüdicke F, Magnette J, Baker G, Weitkunat R.

Biomarkers. 2015;20(6-7):411-21. doi: 10.3109/1354750X.2015.1096303.

22.

Comparison of the Pharmacokinetics of Nicotine Following Single and Ad Libitum Use of a Tobacco Heating System or Combustible Cigarettes.

Picavet P, Haziza C, Lama N, Weitkunat R, Lüdicke F.

Nicotine Tob Res. 2016 May;18(5):557-63. doi: 10.1093/ntr/ntv220. Epub 2015 Oct 5.

23.

A novel approach to assess the population health impact of introducing a Modified Risk Tobacco Product.

Weitkunat R, Lee PN, Baker G, Sponsiello-Wang Z, González-Zuloeta Ladd AM, Lüdicke F.

Regul Toxicol Pharmacol. 2015 Jun;72(1):87-93. doi: 10.1016/j.yrtph.2015.03.011. Epub 2015 Mar 27.

24.

Does the use of ingredients added to tobacco increase cigarette addictiveness?: a detailed analysis.

Sanders E, Weitkunat R, Utan A, Dempsey R.

Inhal Toxicol. 2012 Mar;24(4):227-45. doi: 10.3109/08958378.2012.663006.

25.

Effectiveness of strategies to increase the validity of findings from association studies: size vs. replication.

Weitkunat R, Kaelin E, Vuillaume G, Kallischnigg G.

BMC Med Res Methodol. 2010 May 28;10:47. doi: 10.1186/1471-2288-10-47.

26.

Systematic review of the relation between smokeless tobacco and cancer of the pancreas in Europe and North America.

Sponsiello-Wang Z, Weitkunat R, Lee PN.

BMC Cancer. 2008 Dec 1;8:356. doi: 10.1186/1471-2407-8-356.

27.

Systematic review of the relation between smokeless tobacco and non-neoplastic oral diseases in Europe and the United States.

Kallischnigg G, Weitkunat R, Lee PN.

BMC Oral Health. 2008 May 1;8:13. doi: 10.1186/1472-6831-8-13.

28.

Meta-analysis of the relation between European and American smokeless tobacco and oral cancer.

Weitkunat R, Sanders E, Lee PN.

BMC Public Health. 2007 Nov 15;7:334.

29.

Fibrin glue in coronary artery bypass grafting operations: casting out the Devil with Beelzebub?

Lamm P, Adelhard K, Juchem G, Weitkunat R, Milz S, Kilger E, Götz A, Reichart B.

Eur J Cardiothorac Surg. 2007 Oct;32(4):567-72. Epub 2007 Aug 29.

PMID:
17761433
31.

Occupational acrylonitrile exposure and lung cancer: a meta-analysis.

Sponsiello-Wang Z, Sanders E, Weitkunat R.

J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2006;24(2):257-84.

PMID:
17114112
32.

[Relation between certain diseases and frequency of depression in geriatric patients].

Zietemann V, Zietemann P, Weitkunat R, Kwetkat A.

Nervenarzt. 2007 Jun;78(6):657-64. German.

PMID:
16821065
33.

Retropubic transvesical prostatectomy for significant prostatic enlargement must remain a standard part of urology training.

Adam C, Hofstetter A, Deubner J, Zaak D, Weitkunat R, Seitz M, Schneede P.

Scand J Urol Nephrol. 2004;38(6):472-6.

PMID:
15841780
34.

Risk factors for undervaccination against measles in a large sample of preschool children from rural Bavaria.

Zucs AP, Crispin A, Eckl E, Weitkunat R, Schlipköter U.

Infection. 2004 Jun;32(3):127-33.

PMID:
15188070
35.

Tongue-muscle training by intraoral electrical neurostimulation in patients with obstructive sleep apnea.

Randerath WJ, Galetke W, Domanski U, Weitkunat R, Ruhle KH.

Sleep. 2004 Mar 15;27(2):254-9.

PMID:
15124719
36.

Perceived risk of bovine spongiform encephalopathy and dietary behavior.

Weitkunat R, Pottgiesser C, Meyer N, Crispin A, Fischer R, Schotten K, Kerr J, Uberla K.

J Health Psychol. 2003 May;8(3):373-81.

PMID:
14670215
37.

Biofeedback of R-wave-to-pulse interval normalizes blood pressure.

Rau H, Bührer M, Weitkunat R.

Appl Psychophysiol Biofeedback. 2003 Mar;28(1):37-46.

PMID:
12737095
38.

[The use of medical services and the utilization rate in screening programs in relation to social class: results of a representative survey in Bavaria].

Röckl-Wiedmann I, Meyer N, Fischer R, Laubereau B, Weitkunat R, Uberla K.

Soz Praventivmed. 2002;47(5):307-17. German.

PMID:
12512224
39.
40.

Exploratory causal modeling in epidemiology: are all factors created equal?

Weitkunat R, Wildner M.

J Clin Epidemiol. 2002 May;55(5):436-44.

PMID:
12007545
41.

[Health-related lifestyles and personality traits in fathers of children of minor age. Results of a telephone inquiry].

Grill E, Crispin A, Weitkunat R.

Gesundheitswesen. 2002 Jan;64(1):19-24. German.

PMID:
11791198
42.

Separation from children as a specific risk factor to fathers' health and lifestyles.

Grill E, Weitkunat R, Crispin A.

Soz Praventivmed. 2001;46(4):272-8.

PMID:
11582855
43.

[Population-based health monitoring via computer-assisted telephone interviews in Bavaria].

Fischer R, Meyer N, Weitkunat R, Crispin A, Schotten K, Uberla K.

Gesundheitswesen. 2001 Aug;63 Suppl 2:S123-9. German.

PMID:
11533873
44.

Standardization of non-aggregated data: theory and practice.

Weitkunat R, Crispin A, Grill E, Fischer R, Meyer N, Schotten K.

Comput Methods Programs Biomed. 2001 Jun;65(3):207-27.

PMID:
11339983
45.

[Incidence of operations in Germany via telephone survey in 4 selected cities].

Weitkunat R, Sangha O, Crispin A, Ohmann C, Wildner M.

Gesundheitswesen. 2000 Jul;62(7):365-70. German.

PMID:
10955002
46.

The Berne-Munich Lifestyle Panel. Background and baseline results from a longitudinal health lifestyle survey.

Abel T, Walter E, Niemann S, Weitkunat R.

Soz Praventivmed. 1999;44(3):91-106.

PMID:
10436489
47.

[Development of an epidemiologically based health reporting system].

Wildner M, Weitkunat R.

Gesundheitswesen. 1998 Aug;60 Suppl 1:S11-4. German.

PMID:
9816754
48.

Psychological factors associated with the uptake of measles immunization: findings and implications for prevention.

Weitkunat R, Markuzzi A, Vogel S, Schlipköter U, Koch HJ, Meyer G, Ferring D.

J Health Psychol. 1998 Apr;3(2):273-84. doi: 10.1177/135910539800300210.

PMID:
22021365
49.

[Measles, mumps and rubella vaccination status of school beginners in Munich].

Markuzzi A, Schlipköter U, Weitkunat R, Meyer G.

Soz Praventivmed. 1997;42(3):133-43. German.

PMID:
9334085
50.

[Alcohol in Munich secondary school students--a study for dissemination of experiences, knowledge, attitude and behavior].

Scherer K, Mengistu D, Meyer G, Weitkunat R.

Gesundheitswesen. 1996 Oct;58(10):533-7. German.

PMID:
9035783

Supplemental Content

Loading ...
Support Center